INmune Bio, Inc. (INMB) announced on Tuesday an in-depth analysis of blinded data from its AD02 Phase II Alzheimer's Disease trial, highlighting the exceptional performance of the novel cognitive measure, EMACC. The analysis also revealed a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB).
The results demonstrated a highly significant correlation (p
